Targeting MYC for triple-negative breast cancer treatment

Breast cancer is the most frequently diagnosed form of cancer and the second leading cause of cancer-related death among women in the United States. Triple-negative breast cancer (TNBC) consists of a heterogeneous set of cancers characterized by the lack of hormone receptor expression and human epidermal growth factor receptor 2 (HER2) amplification, and is the most aggressive subtype of breast cancers [1]. Many exciting advances have been made in breast cancer treatment over the past few decades, but effective targeted therapy for TNBC is not available. To make matters worse, drug resistance, metastasis and tumor relapse still frequently occur in TNBC patients after a transient response to initial treatment. This highly unsatisfactory clinic outcome emphasizes an urgent need to develop innovative and more effective therapeutic approaches that can achieve a more durable response in TNBC treatment